Explore the words cloud of the RADAR-AD project. It provides you a very rough idea of what is the project "RADAR-AD" about.
The following table provides information about the project.
Coordinator |
KING'S COLLEGE LONDON
Organization address contact info |
Coordinator Country | United Kingdom [UK] |
Total cost | 7˙640˙145 € |
EC max contribution | 4˙999˙757 € (65%) |
Programme |
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2)) |
Code Call | H2020-JTI-IMI2-2017-12-two-stage |
Funding Scheme | IMI2-RIA |
Starting year | 2019 |
Duration (year-month-day) | from 2019-01-01 to 2022-06-30 |
Take a look of project's partnership.
There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials. The objectives are to 1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies; 2) Optimise the RADAR-CNS platform for use in AD studies; 3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage; 4) Perform statistical modelling to estimate longitudinal predictions; 5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions. Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.
Focus group report on ADLs that can be monitored with RMT | Documents, reports | 2020-02-12 18:04:34 |
Generic press release to be used by all partners | Websites, patent fillings, videos etc. | 2020-02-12 18:04:40 |
Launch of website | Websites, patent fillings, videos etc. | 2020-02-11 09:54:05 |
Research protocol | Documents, reports | 2020-02-11 09:54:05 |
Report on Kick-Off meeting | Documents, reports | 2020-02-11 09:54:05 |
Preliminary Prioritized list of functional domains | Documents, reports | 2020-02-11 09:54:05 |
Develop visual identity and communication strategy | Documents, reports | 2020-02-11 09:54:05 |
Take a look to the deliverables list in detail: detailed list of RADAR-AD deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RADAR-AD" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RADAR-AD" are provided by the European Opendata Portal: CORDIS opendata.
Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors
Read More